Biochem/physiol Actions

Primary TargetNMDA receptors

Target IC₅₀: 0.13, 0.068, 0.087, and 0.14 µM for NR2A –D, respectively.

General description

A non-competitive, subunit non-selective, potent antagonist for NMDA receptors (IC₅₀ = 0.13, 0.068, 0.087, and 0.14 µM for NR2A - D, respectively). Widely used as neuroprotective agent after acute traumatic brain injury and stroke in animal researches.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Reddy, N., et al. 1994. J. Medicinal Chemistry.37, 260.r>Muir, K., et al. 1994. British J. Clinical Pharmacol.38, 33.Schäbitz, W., et al. 2000. Stroke.31, 1709.Hoyte, L., et al. 2004. Current Molecular Medicine.4, 131.Turner, R., et al. 2013. J. of Neurosurgery.1, 14.

Packaging

10 mg in Glass bottle

Physical form

Supplied as a hydrochloride salt.

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Standard Handling (A)